Roth Capital Positive on Heat Biologics (HTBX) as HS-110 Combo Phase 1b Enrollment Resumes
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- S&P 500 ends up slightly with boost from financials; Netflix up late
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- La Quinta Holdings (LQ) Gains on Plan to Split in Two
- After-Hours Stock Movers 01/18: (OCLR) (CSX) (NFLX) Higher; (AMDA) (RCII) (ZYNE) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Roth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 after the company announced resumption enrollment in its Phase 1b trial evaluating HS-110 in combination with nivolumab (Opdivo).
Analyst Joseph Pantginis commented today,
We believe that trial resumption for HS-110 in combination with nivolumab for NSCLC signals a positive view of the data showing an increase in CD8+ T cells in biopsy samples that derived from tumors originally classified as cold. As cold tumors tend to be less responsive to checkpoint inhibitor monotherapy, we believe that if HS-110 increases T cell infiltration it may sensitize the tumors to other therapies resulting in positive outcomes. We hope to get a better perspective on T cell tumor infiltration when HTBX releases additional data, as topline data for the patients to be enrolled in the NSCLC trial are expected within the next twelve months. In addition, HTBX expects to report topline 6-month data for the original eight patients in 4Q16.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
- Deutsche Bank Raises Price Target on IHS Markit (INFO) to $44; Reiterates Buy
- Jefferies Raises Price Target on Symantec (SYMC) to $27; Reiterates Hold
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital, S1
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!